Additional Information
Market: NYSE
Sector: Support Services
EPIC: MMM
Latest Price: 87.73  (0.34% Ascending)
52-week High: 97.97
52-week Low: 70.93
Market Cap: 62,247.60M
1 year chart
1 day chart

3M is a diversified technology company with worldwide exposure to the health care, safety, industrial, telecommunications, electronics, security and protection services and transportation markets.

3M Acquires Patient Warming Products Manufacturer Arizant For $810M

9th Sep 2010, 6:13 pm
3M Acquires Patient Warming Products Manufacturer Arizant For $810M

Health product maker 3M (NYSE:MMM) has agreed to acquire Arizant, a Minnesota-based manufacturer of patient warming solutions in surgical settings, for $810 million in cash.

Because anesthetized patients can’t regulate their own body temperature, Arizant products help maintain normal body temperature in surgical patients in order to prevent hypothermia.

The company’s product line includes its Bair Paws patient warming gown and its Ranger blood and fluid warming systems. 

Arizant currently employs 375 people globally and the company's sales for 2010 are expected to be approximately $200 million.

"Patient warming is a highly strategic adjacency for our business and integral to infection prevention," said president and general manager of the 3M infection prevention division Debra Rectenwald.

The acquisition is expected to expand 3M's infection prevention offerings and help drive growth internationally, as well as provide a platform of new wound care technologies.

3M's infection prevention segment helps hospitals reduce healthcare-associated infections. It produces sterilization and monitoring products, as well as products for hand hygiene, pre-operative preps, and surgical drapes.

On a non-adjusted basis, 3M estimates the acquisition to be $0.03 dilutive to earnings for the 12 month period following the close of the transaction.

The company expects the acquisition to have no effect on earnings for the same period after adjusting for integration expenses and the effects of purchase accounting.

The deal is expected to close in the fourth quarter.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.